Requests for Reconsideration at the Division Level Under GDUFA
This draft guidance provides recommendations on the procedures for applicants of abbreviated new drug applications (ANDAs) that wish to pursue a request for reconsideration within the review discipline at the division level or original signatory authority.
Guidance Issuing Office Division Level Under Drug Administration Docket Number Drug Evaluation Generic Drug User Fee Amendments
Source: fda.gov